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Abstract
The effect of substances which alter extracellular dopamine (DA) concentration has been studied by
measuring changes in the binding of radiolabelled raclopride, a DA D2 receptor ligand that is sensitive to
endogenous DA. To better characterize the relationship between extracellular DA concentration and DA
D2 receptor binding of raclopride, we compared the changes of extracellular DA concentration (measured
using in-vivomicrodialysis) and in-vivo [3H]raclopride binding induced by different doses of methamphet-
amine (Meth) and nicotine, drugs that enhance DA release with and without blocking DA transporters
(DATs), respectively, in rat striatum. Nicotine elicited a modest increase of striatal extrasynaptic extra-
cellular DA, while Meth produced a marked increase of striatal extrasynaptic DA in a dose-dependent
manner. There was a close correlation between the decrease in [3H]raclopride in-vivo binding and the
increase in extrasynaptic DA concentration induced by both nicotine (r2=0.95, p<0.001) and Meth
(r2=0.98, p=0.001), supporting the usefulness of the radiolabelled raclopride-binding measurement for
the non-invasive assessment of DA release following interventions in the living brain. However, the linear
regression analysis revealed that the ratio of percent DA increase to percent [3H]raclopride binding re-
duction was 25-fold higher for Meth (34.8 : 1) than for nicotine (1.4 : 1). The apparent discrepancy in the
extrasynaptic DA–[3H]raclopride binding relationship between the DA-enhancing drugs with and with-
out DAT-blocking property indicates that the competition between endogenous DA and radiolabelled
raclopride takes place at the intrasynaptic rather than extrasynaptic DA D2 receptors and reflects synaptic
concentration of DA.
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Introduction
Investigating changes in synaptic dopamine (DA) con-
centration in response to pharmacological challenges
in vivo in the human brain is a valuable tool in human
neuropharmacology. Positron emission tomography
(PET) and single-photon emission computed tomog-
raphy (SPECT) neuroreceptor imaging techniques can
be used to measure acute fluctuations in synaptic
concentration of neurotransmitters. Competition be-
tween endogenous transmitters and radioligands for
binding to neuroreceptors is the principle underlying
this application. Rodent (Inoue et al. 1991 ; Kim et al.
1998 ; Ross & Jackson, 1989 ; Young et al. 1991), non-
human primate (Carson et al. 1997 ; Dewey et al. 1993 ;
Hartvig et al. 1997 ; Volkow et al. 1999) and human
studies (Schlaepfer et al. 1997 ; Smith et al. 1998 ;
Volkow et al. 1994 ; Wang et al. 1999) have suggested
that changes attributable to synaptic DA can be shown
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using ligands such as [11C/3H]raclopride, a DA D2
receptor radioligand that is sensitive to endogenous
DA. PET studies using [11C]raclopride have been suc-
cessfully applied to characterize alterations of DA
transmission in pharmacological and clinical con-
ditions by measuring changes in the binding potential
of the radioligand (Breier et al. 1997; Kim et al. 2004;
Koepp et al. 1998 ; Volkow et al. 1997).
We have previously reported, in an abstract form
(where the dose of nicotine was expressed as nicotine
salt ; Kim et al. 1998), that nicotine, a drug that en-
hances DA release without blocking DA transporters
(DATs), induced a significant decrease in [3H]raclo-
pride in-vivo binding with only a modest increase
in extrasynaptic extracellular DA concentration meas-
ured with in-vivomicrodialysis. In contrast, the dose of
amphetamine (a DA releaser having DAT-blocking
property) associated with a similar decrease in
[11C]raclopride binding in monkeys elicited a much
larger increase in extrasynaptic extracellular DA
(Breier et al. 1997). Similar discrepancies have been
shown between DA enhancers with and without
DAT-blocking property in their ability to affect DA
microdialysis and [11C]raclopride binding potential
measurements (Tsukada et al. 1999). Based on these
observations, it has been suggested that the compe-
tition between endogenous DA and radioligand takes
place at the intrasynaptic rather than extrasynaptic
D2 receptors and reflects the synaptic concentration of
DA (Laruelle, 2000). Further validation studies directly
comparing the extracellular DA–raclopride binding
relationships associated with DA-enhancing drugs
with and without DAT-blocking property are needed.
In the present study we report different relationships
between the effects of methamphetamine (Meth) and
nicotine, drugs that enhance DA release with and
without blocking DATs, respectively. Our data further
support the notion that changes in radiolabelled
raclopride binding are mediated by changes in syn-
aptic rather than extrasynaptic DA concentration.
Materials and methods
Animals
Male Sprague–Dawley rats, weighing 280–320 g,
were used for in-vivo microdialysis and in-vivo
[3H]raclopride binding experiments. The animals were
group-housed in light-, temperature-, and humidity-
controlled animal quarters with food and water avail-
able ad libitum. All procedures involving animal use
were in strict accordance with the NIH Guide for
the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care and Use
Committee.
Drugs
(x)-Nicotine hydrogen tartrate was purchased from
Sigma Chemical Co. (St Louis, USA). S(+)-Meth-
amphetamine HCl was obtained from RBI (Natick,
USA). [3H]Raclopride (79.3 Ci/mmol) was purchased
from NEN Life Science (Boston, USA).
Surgery and microdialysis procedures
Extrasynaptic extracellular DA concentrations were
monitored in the striatum of freely moving rats fol-
lowing the different doses of nicotine (0.1–10 mg/
kg s.c. ; expressed as free base) and Meth (0.1–10 mg/
kg i.p.) using in-vivo microdialysis. Rats were anaes-
thetized with sodium pentobarbital (50 mg/kg i.p.).
Using aseptic techniques, a guide cannula (CMA/12,
CMA Microdialysis, Solna, Sweden) aimed to termin-
ate in the centre of the striatum (AP 1.0, L 3.2 from
bregma; H 3.0 from dura; Paxinos & Watson, 1986)
was stereotaxically implanted and attached to the
skull using skull screws and dental cement. The can-
nula was then closed with a tight-fitting stainless-steel
obturator. The microdialysis was performed in freely
moving rats. Following 3-d recovery, a 4-mm micro-
dialysis probe (CMA/12, CMA Microdialysis) con-
nected via a dual liquid swivel to a syringe pump was
inserted into the guide cannula and perfused with an
artificial cerebrospinal fluid [145 mM NaCl, 2.7 mM
KCl, 1.2 mM CaCl2, 1.0 mM MgCl2, 2.0 mM Na2HPO4
(pH 7.4)] at a constant rate of 1.5 ml/min. Dialysate
samples were collected during 20-min sampling in-
tervals via outlet tubing connected to a microfraction
collector (CMA Microdialysis). The position of the
probes was verified by histological examination at
the end of experiments.
Analytical procedures
The dialysate (injection volume 30 ml) was assayed
for DA using HPLC coupled to an ESA Coulochem II
5200A electrochemical detection system (ESA Bio-
sciences, USA) with an oxidation potential of
+320 mV. The detector was equipped with a high
performance analytical cell (ESA model 5014) which is
tailored for use in microdialysis applications. The
mobile phase was composed of 75 mM monobasic so-
dium phosphate, 0.1 mM EDTA, 1.4 mM octanesulfonic
acid and 10% acetonitrile and adjusted to pH 3.2
with HPLC grade phosphoric acid. The separation of
monoamine metabolites was performed on a Waters
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Nova-Pak C-18 column (4 mm, 150r3.9 mm). The flow
rate of the system was 1.0 ml/min. DA in dialysates
was expressed as a percentage of three baseline
samples collected immediately before drug treatment.
In-vivo [3H]raclopride-binding experiments
Rats received different doses of nicotine (0.1–10 mg/kg
s.c. ; expressed as free base) orMeth (0.1–10 mg/kg i.p.)
20 min before injection of [3H]raclopride. Control ani-
mals were injected with the same volume (0.5 ml) of
saline. [3H]Raclopride (10 mCi in 0.5 ml saline) was
injected intravenously into a tail vein, and 20 min later,
the animals were sacrificed by cervical dislocation.
Striata and cerebella were immediately dissected on
ice,weighed andplaced into glass vials. After digestion
of the tissues with Soluene-350 (Packard Instrument
Co., USA), 10 ml Formula 989 scintillator (Packard)
were added and the samples counted in a liquid
scintillation counter (Tri-Carb 2500 TR, Packard).
In-vivo binding of [3H]raclopride to DA D2 receptors
was expressed as the ratio of specific (striatal –
cerebellar) to non-specific (cerebellar) uptake.
Relationship between extrasynaptic extracellular DA
concentration and in-vivo [3H]raclopride binding
To evaluate the relationship between extrasynaptic
DA concentration and in-vivo [3H]raclopride binding
in the striatum, the percentage changes of striatal
[3H]raclopride binding induced by various doses of
nicotine or Meth were plotted against the percentage
changes of DA concentration in striatal extracellular
fluid sampled at 40 min after drug treatment. DA
concentration in 40-min microdialysis samples de-
notes the average DA concentration between 20
and 40 min after drug administration, during which
[3H]raclopride binding occurred.
Statistical analysis
Values are expressed as mean¡S.E.M. Microdialysis
data were analysed by one- and two-way (treat-
mentrtime) analysis of variance (ANOVA) with re-
peated measures, followed by Fisher’s PLSD post-hoc
test. In-vivo [3H]raclopride-binding data were ana-
lysed by one-way ANOVA and Fisher’s PLSD test. The
relationship between extrasynaptic DA concentration
and [3H]raclopride binding was analysed with the
Pearson linear correlation coefficient. A probability
value of 0.05 was selected as the significance level.
Results
Nicotine-induced changes in extrasynaptic
extracellular DA concentration and in-vivo
[3H]raclopride binding
Table 1 shows [3H]raclopride uptake in the striatum
and cerebellum, expressed as percentage of injected
dose per gram of tissue (%ID/g tissue), as well as the
(striatum – cerebellum)/cerebellum ratios at various
doses of nicotine including control values. There was
no significant difference in cerebellar [3H]raclopride
uptake in controls and animals treated with different
doses of nicotine, while striatal uptake decreased sig-
nificantly with increasing doses of nicotine within a
limited dose range. Figure 1(a, c, e) shows the effect of
nicotine on extrasynaptic DA concentration and its
relationship with in-vivo binding of [3H]raclopride in
the striatum [expressed as the (striatum – cerebellum)/
cerebellum ratio]. Subcutaneous injection of nicotine
(0.1–10 mg/kg) elicited a modest increase of striatal
extrasynaptic DA and a decrease of striatal [3H]raclo-
pride binding in a dose-dependent manner within a
limited dose range. A dose of 1.8 mg/kg nicotine in-
duced a 30.8¡8.3% increase in extrasynaptic DA over
Table 1. [3H]Raclopride striatal and cerebellar uptake data at different doses of nicotine
Dose of nicotine (mg/kg)
0 (Control) 0.1 0.4 1.8 3.5 7 10
%ID/g
Striatum (S) 3.698¡0.237 3.602¡0.276 3.594¡0.230 2.944¡0.194* 2.624¡0.155** 2.512¡0.219** 2.516¡0.182**
Cerebellum (C) 0.485¡0.038 0.469¡0.044 0.464¡0.036 0.471¡0.040 0.480¡0.033 0.459¡0.036 0.466¡0.031
S/C ratio – 1 6.651¡0.427 6.716¡0.450 6.798¡0.596 5.272¡0.360* 4.484¡0.215** 4.508¡0.551** 4.410¡0.177**
%ID/g=percent injected dose per gram tissue.
Data are means¡S.E.M. (n=4–6 for each group).
* p<0.05, ** p<0.005 vs. the control group.
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baseline level at the peak time of 40 min after injection
(p<0.01). This dose of nicotine resulted in a 20.7¡
5.4% decrease in [3H]raclopride binding compared
with control values (5.272¡0.360 vs. 6.651¡ 0.427,
p<0.05). Increasing the dose of nicotine (3.5 mg/kg)
led to a further increase in extrasynaptic DA by
51.2¡9.1% at the peak time of 40 min after injection
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Fig. 1. Effects of nicotine and methamphetamine (Meth) on extrasynaptic dopamine (DA) concentration and their relationships
with in-vivo binding of [3H]raclopride in the striatum [(a, c, e) for nicotine and (b, d, f) for Meth]. Microdialysis data (a, b) are
expressed as a percentage of three baseline samples and are means¡S.E.M. of 4–6 independent experiments. Arrows indicate the
time of nicotine or Meth treatment. The percentage changes of striatal [3H]raclopride binding induced by various doses of
nicotine or Meth were plotted against the percentage changes of DA concentration in striatal extracellular fluid sampled at
40 min after drug treatment (c–f). The percentage change data for extrasynaptic DA concentration and [3H]raclopride binding
are means¡S.E.M. of 4–6 independent experiments. The numbers at each data-point are doses (in mg/kg) of nicotine (e) or
Meth (f) for the data-points. Nic, nicotine.
836 S. E. Kim and S.-M. Han
32.6¡3.2% (4.484¡0.215 vs. 6.651¡0.427, p<0.005).
When the nicotine dose was increased to 7 and
10 mg/kg, neither extrasynaptic DA nor [3H]raclo-
pride binding were changed further compared with
3.5 mg/kg nicotine. Lower doses of nicotine (0.1 and
0.4 mg/kg) had no significant effect on either extra-
synaptic DA or [3H]raclopride binding in the striatum.
The decrease in [3H]raclopride binding was plotted
against the increase in extrasynaptic DA concentration
(Fig. 1e). There was a close correlation between the
decrease in [3H]raclopride in-vivo binding and the
increase in extrasynaptic DA concentration induced
by nicotine (r2=0.95, p<0.001). The linear regression
analysis revealed that 1% reduction of [3H]raclopride
binding corresponds to a 1.4% increase in extra-
synaptic DA concentration.
Meth-induced changes in extrasynaptic extracellular
DA concentration and in-vivo [3H]raclopride binding
Table 2 shows [3H]raclopride uptake in the striatum
and cerebellum, expressed as %ID/g tissue, as well as
the (striatum – cerebellum)/cerebellum ratios at vari-
ous doses of Meth including control values. There was
no significant difference in cerebellar [3H]raclopride
uptake among controls and animals treated with dif-
ferent doses of Meth, while striatal uptake decreased
significantly with increasing doses of Meth. Figure 1(b,
d, f) shows the effect of Meth on extrasynaptic DA
concentration and its relationship with in-vivo binding
of [3H]raclopride in the striatum [expressed as the
(striatum – cerebellum)/cerebellum ratio]. In contrast
to nicotine, intraperitoneal injection of Meth (0.1–
10 mg/kg) produced a marked increase of striatal
extrasynaptic DA in a dose-dependent manner. How-
ever, it induced a dose-dependent decrease in striatal
[3H]raclopride binding only with a similar magnitude
to that attained by nicotine. Doses of 0.1–10 mg/kg
Meth elicited 118–1371% increases in extrasynaptic
DA over baseline level at the peak time of 40 min after
injection (p<0.01–0.0001), while these doses of Meth
caused only 5.9–42.1% decreases in [3H]raclopride
binding compared with control values (5.504¡0.123–
3.388¡0.369 vs. 5.848¡0.269, p<0.05–0.00001). The
decrease in [3H]raclopride binding was plotted
against the increase in extrasynaptic DA concentration
(Fig. 1 f). There was a close correlation between the
decrease in [3H]raclopride in-vivo binding and the
increase in extrasynaptic DA concentration induced
by Meth (r2=0.98, p=0.001). The linear regression
analysis revealed that 1% reduction of [3H]raclopride
binding corresponds to a 34.8% increase in extra-
synaptic DA concentration.
Discussion
We found a close correlation between the decrease in
[3H]raclopride in-vivo binding and the increase in
extrasynaptic DA concentration induced by both
nicotine and Meth, supporting the usefulness of the
radioligand-binding measurement in providing non-
invasive assessment of DA release.
If the competition between endogenous DA and
radioligand occurs mostly at non-synaptic DA D2 re-
ceptors, microdialysis measurements of extrasynaptic
DA and decrease in [3H]raclopride binding would
be related across pharmacological challenges. How-
ever, our data demonstrate that the extrasynaptic
DA–[3H]raclopride binding relationship is quite dif-
ferent following Meth and nicotine, drugs that en-
hance DA release with and without blocking DATs,
respectively. A large increase in extrasynaptic DA
concentration induced by Meth was associated with a
relatively small effect on [3H]raclopride binding. The
ratio of percent DA increase to percent binding re-
duction was 34.8 :1 for Meth. This is consistent with
Table 2. [3H]Raclopride striatal and cerebellar uptake data at different doses of methamphetamine
Dose of methamphetamine (mg/kg)
0 (Control) 0.1 0.5 1 5 10
%ID/g
Striatum (S) 3.281¡0.166 3.148¡0.191 2.931¡0.134 2.919¡0.169* 2.529¡0.224** 2.155¡0.140***
Cerebellum (C) 0.481¡0.023 0.486¡0.007 0.479¡0.008 0.492¡0.023 0.504¡0.038 0.494¡0.022
S/C ratio – 1 5.848¡0.269 5.504¡0.123 5.143¡0.322 4.954¡0.293* 4.037¡0.283** 3.388¡0.369***
%ID/g=percent injected dose per gram tissue.
Data are means¡S.E.M. (n=4–6 for each group).
* p<0.05, ** p<0.0005, *** p<0.00001 vs. the control group.
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the ratios of amphetamine-induced DA release to
[123I]iodobenzamide (44:1 ; Laruelle et al. 1997) and
[11C]raclopride (44–64:1 ; Breier et al. 1997) binding
potential reductions. In contrast, as revealed in the
present study, the ratio of percent DA increase to
percent [3H]raclopride binding reduction was 1.4 :1 for
nicotine. As a consequence, a similar reduction in
[3H]raclopride binding (y30%) was observed follow-
ing nicotine (3.5 mg/kg) and Meth (5 mg/kg) chal-
lenges associated with 51% and 826% increase in
extrasynaptic DA, respectively. Extrasynaptic DA re-
flects intrasynaptic DA following DAT blockers such
as amphetamine and Meth, but not following drugs
like nicotine, which enhances DA release without
blocking DAT (Laruelle, 2000). Hence, the apparent
discrepancy in the extrasynaptic DA–[3H]raclopride
binding relationship following Meth and nicotine
indicates that the competition between endogenous
DA and radiolabelled raclopride takes place at the
intrasynaptic rather than extrasynaptic DA D2 recep-
tors and reflects synaptic concentration of DA. It might
be that extrasynaptic D2 receptors are less sensitive
to endogenous DA, conceivably due to their con-
figuration in the agonist low-affinity state. Similarly, a
PET study combined with microdialysis reported that
at similar level of [11C]raclopride binding-potential
decrease, the magnitude of extracellular DA increase
following direct DA enhancers (DAT blockers : GBR
12909 and Meth) was much larger than following in-
direct enhancers (a muscarinic cholinergic antagonist
benztropine and a 5-HT2A antagonist ketanserin ;
Tsukada et al. 1999). These results also are consistent
with a predominant intrasynaptic location of the effect
measured with PET.
Grace (1991, 1993) proposed the term ‘phasic re-
lease’ to characterize the intrasynaptic release of DA
elicited by cell firing, and the term ‘tonic release’ to
characterize the low level of extrasynaptic release that
is independent of cell firing. In this sense, endogenous
competition studies using radiolabelled benzamides
are of great use for the assessment of phasic activity of
dopaminergic neurons in neuropsychiatric disorders
such as schizophrenia (Abi-Dargham et al. 2000),
attention deficit hyperactivity disorder (Grace, 2001)
and cognitive conditions associated with novel and
rewarding stimuli (Kim et al. 2004 ; Koepp et al. 1998;
Schultz, 2000).
In the present study, the magnitude of reductions of
in-vivo [3H]raclopride binding by nicotine and Meth
did not exceed 50% of control values. These results are
consistent with PET and SPECT studies in non-human
primates and humans that indicate that only up to
50% of the in-vivo binding of [11C]raclopride and
[123I]iodobenzamide is affected by psychostimulant
challenges (Abi-Dargham et al. 1998 ; Booij et al. 1997;
Breier et al. 1997; Dewey et al. 1993 ; Laruelle et al.
1995, 1997 ; Volkow et al. 1994, 1997, 1999 ; Wang et al.
1999). This ceiling effect may be explained by several
factors, such as DA D2 receptors configured in a state
of low affinity for the agonist DA, D2 receptors oc-
cupied by baseline levels of endogenousDA, and extra-
synaptic D2 receptors that might be less exposed to
changes in DA release compared with receptors lo-
cated in the synaptic cleft (Laruelle, 2000). Narendran
et al. (2005) showed that a large proportion (70–80%)
of DAD2 receptors configured in a state of high affinity
for agonists in vivo using the D2 receptor agonist
[11C]N-propyl-norapomorphine (NPA) and the D2
receptor antagonist [11C]raclopride in PET studies in
baboons. This may explain the vulnerability of D2
radiotracers to competition by endogenous DA. They
also showed that at a tracer dose, [11C]NPA binding
potential was almost exclusively associated with high-
affinity state receptors, suggesting that the in-vivo
binding of agonist radiotracer [11C]NPA is more vul-
nerable to competition by endogenous DA than that
of the antagonist radiotracer [11C]raclopride.
Tsukada et al. (2002) found that nicotine at
y0.06 mg/kg or 0.18 mg/kg did not cause [11C]raclo-
pride displacement in the striatum of conscious
monkeys, but a small effect was seen in the same
animals under isoflurane anaesthesia. Marenco et al.
(2004) also reported that nicotine doses ranging from
0.01 to 0.06 mg/kg produced only 5% reduction in
[11C]raclopride binding potential in monkeys under
isoflurane anaesthesia. These non-human primate
PET data are consistent with our findings that doses
of nicotine <0.4 mg/kg did not cause changes in
[3H]raclopride binding in rats. Moreover, the observed
magnitude of changes in [3H]raclopride binding after
Meth administration is comparable to non-human
primate PET data (Marenco et al. 2004 ; Tsukada et al.
2002).
As shown in the present study, it is obvious that
Meth causes a much larger increase in extrasynaptic
DA than nicotine. This is probably due to the different
mechanisms of action of the two drugs. Meth blocks
DATs and causes presynaptic DA release (Kuczenski
& Segal, 1989), while nicotine presumably increases
burst firing of dopaminergic neurons for a short
period of time (Grenhoff et al. 1986 ; Murase et al. 1993).
In this study, systemic injection of nicotine produced
only a modest increase in striatal DA output. It is
known that the nigrostriatal system is less sensitive to
the effects of nicotine than the mesolimbic system
(Di Chiara & Imperato, 1988 ; Imperato et al. 1986;
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Mereu et al. 1987). We found that nicotine-induced
striatal DA output reached a plateau at a dose of
nicotine higher than 3.5 mg/kg. This may be due to
several factors, such as possible curvilinear relation-
ship between the nicotine dose administered and the
magnitude of nicotinic acetylcholine receptor occu-
pancy, rapid desensitization of nicotinic acetylcholine
receptors (Grady et al. 1994), nicotinic acetylcholine
receptor modulation of DAT function and thereby
enhancement by nicotine of DA clearance (Middleton
et al. 2004), and distinct allosteric states of the nicotinic
acetylcholine receptor with different affinities for
agonists (Krauss et al. 2000).
This study has limitations. First, we determined
[3H]raclopride-specific binding associated with nic-
otine and Meth using striatal and cerebellar uptake
at the single time-point after tracer administration,
not by measuring kinetics of ligand-receptor binding.
Pharmacological interventions that produce significant
changes in synaptic DA concentration frequently affect
physiological parameters such as body temperature,
regional cerebral blood flow, peripheral clearance, or
non-specific binding of radiotracer, which are known
to affect radiotracer uptake. This raises the importance
of model-basedmethods that are resistant to variations
in these physiological parameters for appropriate
evaluation of the effect of pharmacological challenges
on receptor availability. Nevertheless, in the present
study, doses of either nicotine or Meth did not alter
cerebellar [3H]raclopride uptake at the time of eutha-
nasia compared with control values, while striatal
uptake decreased with increasing doses of nicotine
and Meth. Therefore, we believe that the nicotine-
and Meth-induced decrease in [3H]raclopride-specific
binding represents a reduction in binding potential,
not resulting from challenge-induced changes in
physiological parameters. Second, we could not com-
pare the extrasynaptic DA andDAD2 receptor-binding
data obtained from the same animals. In-vivo imaging
studies combined with microdialysis would allow the
comparison within the same animals.
Conclusion
The close correlation between the decrease in
[3H]raclopride in-vivo binding and the increase in
extrasynaptic DA concentration supports the useful-
ness of the radiolabelled raclopride-binding measure-
ment for the non-invasive assessment of DA release
following pharmacological and non-pharmacological
interventions in the living brain. However, we further
demonstrated that the extrasynaptic DA–[3H]raclo-
pride binding relationship is quite different following
Meth and nicotine, drugs that enhance DA release
with and without blocking DATs, respectively. The
ratio of percent DA increase to percent [3H]raclopride
binding reduction was 25-fold higher for Meth (34.8 :1)
than for nicotine (1.4 :1). The apparent discrepancy
between the drugs with and without DAT-blocking
property indicates that the competition between en-
dogenous DA and radiolabelled raclopride takes place
at the intrasynaptic rather than extrasynaptic DA D2
receptors and reflects synaptic concentration of DA.
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